GlassScriptPhysician profile
Michael Harwood
NPI 1407962236
$771.74
in general payments reported to CMS, 2019-2025
17 companies · $86.88 in 2025
The $86.88 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28.31 · 2020: $37.78 · 2021: $138 · 2022: $135 · 2023: $218 · 2024: $128 · 2025: $86.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $433.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $433.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $234.68 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| E.R. Squibb & Sons, L.L.C. | $118.16 | 2022-2023 | Eliquis |
| Pfizer INC. | $80.15 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.85 | 2021-2025 | Xifaxan, Trulance |
| Abbvie INC. | $50.23 | 2021 | |
| Amgen INC. | $47.22 | 2024-2025 | Otezla, Repatha, Repatha |
| Abbott Laboratories | $22.36 | 2025 | Freestyle Libre 3 |
| Edwards Lifesciences Corporation | $20.99 | 2020 | |
| Sanofi-Aventis U.S. LLC | $19.31 | 2023 | |
| Phathom Pharmaceuticals, INC. | $18.74 | 2024 | Voquezna |
| Janssen Pharmaceuticals, INC | $17.93 | 2023 | Xarelto |
| Lilly USA, LLC | $17.44 | 2021 | |
| Glaxosmithkline, LLC. | $15.15 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $14.19 | 2022 | |
| Sanofi Pasteur INC. | $13.65 | 2023 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $13.08 | 2019 | |
| Nevro Corp. | $12.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Harwood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.